Myelodysplastic Syndromes: all 2,165 studies
Page 19 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic SyndromeCompletedNCT00488436Phase 4
- SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
- AVIDA The Vidaza® (Azacitidine) Patient RegistryCompletedNCT00481273
- Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadCompletedNCT00481143Phase 4
- Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative TherapyCompletedNCT00469729Phase 2/3
- Safety, Tolerability, and Efficacy of Deferasirox in MDSCompletedNCT00469560Phase 3
- Effects of Antithymocyte Globulin in Adults With Myelodysplastic SyndromeStatus unknownNCT00466843Phase 2
- Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other DiseaseStatus unknownNCT00462657Not applicable
- Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological MalignanciesCompletedNCT00460694Phase 1/2
- Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00459524
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00459212Phase 1
- A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic SyndromesTerminatedNCT00458159Phase 1
- Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200CompletedNCT00455910Phase 2
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3
- Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over LoadCompletedNCT00452660Phase 4
- Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesCompletedNCT00451997Phase 2
- A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)WithdrawnNCT00446602Phase 2
- A Phase II Study of Maintenance With Azacitidine in MDS PatientsTerminatedNCT00446303Phase 2
- Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)Status unknownNCT00443339Phase 2
- Effectiveness of Protected Environment Rooms for AML and MDSTerminatedNCT00443300
- Velcade in Myelodysplastic Syndrome - Pilot StudyTerminatedNCT00440076Phase 2
- Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other DiseasesCompletedNCT00438958Phase 3
- Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic AcidStatus unknownNCT00437450Phase 2
- Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of MyelodysplasiaStatus unknownNCT00434239Early Phase 1
- GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid MalignanciesCompletedNCT00426205Not applicable
- Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal MetastasesCompletedNCT00424242Early Phase 1
- Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]Status unknownNCT00424229Phase 2
- Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseNo longer availableNCT00423826
- Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)CompletedNCT00422890Phase 3
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)CompletedNCT00413114Phase 2
- Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic SyndromesCompletedNCT00411905Phase 1/2
- Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
- Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00402558Phase 1
- AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDSWithdrawnNCT00396968Phase 1/2
- Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00394381Phase 1/2
- Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingNCT00392353Phase 1/2
- Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic SyndromesCompletedNCT00380653Phase 1
- Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesCompletedNCT00376922Not applicable
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell TransplantCompletedNCT00376480Phase 1
- Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell TransplantationCompletedNCT00374933Phase 1
- MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic MalignanciesTerminatedNCT00356928Phase 1
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)CompletedNCT00350818Phase 1
- Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerCompletedNCT00346359Phase 2
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDSCompletedNCT00339196Phase 2
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic SyndromesSuspendedNCT00329498Phase 2
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood TransplantationStatus unknownNCT00328237Phase 2
- Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
- A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2
- A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic SyndromesCompletedNCT00324194Phase 1
- A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic SyndromesCompletedNCT00324129Phase 1
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
- Identifying Characteristics of Bone Marrow Failure SyndromesStatus unknownNCT00315419
- T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell TransplantationTerminatedNCT00306332Phase 3
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family DonorStatus unknownNCT00304720Phase 2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
- A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.CompletedNCT00300664Phase 2/3
- Phase I Study of Sequential Cord Blood TransplantsCompletedNCT00299767Phase 1
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaStatus unknownNCT00295997Not applicable
- Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseaseCompletedNCT00295971Phase 1
- Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerCompletedNCT00290641Not applicable
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable
- Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)CompletedNCT00285259Phase 2
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00283114Phase 1
- A Clinical Trial of Decitabine in Patients With Myelodysplastic SyndromeTerminatedNCT00282399Phase 1
- Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow TransplantCompletedNCT00281814
- Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow TransplantationCompletedNCT00281801
- Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)CompletedNCT00280631Phase 1/2
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative DisorderCompletedNCT00274820Phase 2
- Study of Velcade and Thalidomide in Patients With MyelodysplasiaTerminatedNCT00271804Phase 1
- Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic MalignanciesCompletedNCT00270881Phase 1/2
- Safety of Peptide Vaccination for Patients With Myelodysplastic SyndromeCompletedNCT00270452Phase 1
- Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
- Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
- G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic DisordersTerminatedNCT00253552Not applicable
- A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic SyndromeTerminatedNCT00251511Phase 2
- The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic SyndromesWithdrawnNCT00247026Phase 1/2
- Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic MalignanciesCompletedNCT00246662Phase 1
- T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)Status unknownNCT00242515Phase 1/2
- Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)Status unknownNCT00234143Phase 2/3
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00234000Phase 1
- A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)CompletedNCT00230321Phase 1/2
- To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity ConditioningWithdrawnNCT00226512Phase 3
- Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT00225992Phase 2
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
- Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic SyndromesCompletedNCT00217386Phase 2
- New York Blood Center National Cord Blood ProgramTerminatedNCT00212407Early Phase 1